The first phase III clinical trial on a multivalent HFMD vaccine in the worldDecember 13, 2024, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a

On July 20, 2024, Sinovac Biotech Ltd. ("SINOVAC" or the "Company") and the China Foundation for Hepatitis Prevention and Control successfully jointly held the "Hepatitis A Pr

Beijing, China – June 18, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its PROV

On June 4, 2024, Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin met with Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, in Beijing, China. Vice-Pr

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and E

Beijing, China – April 12, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its Pol

Beijing, China – March 27, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Com

Beijing, China – January 11, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Reass